Ruth Motter

11.5k total citations · 2 hit papers
25 papers, 2.6k citations indexed

About

Ruth Motter is a scholar working on Physiology, Molecular Biology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Ruth Motter has authored 25 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Physiology, 8 papers in Molecular Biology and 6 papers in Cellular and Molecular Neuroscience. Recurrent topics in Ruth Motter's work include Alzheimer's disease research and treatments (18 papers), Dementia and Cognitive Impairment Research (4 papers) and Amyloidosis: Diagnosis, Treatment, Outcomes (4 papers). Ruth Motter is often cited by papers focused on Alzheimer's disease research and treatments (18 papers), Dementia and Cognitive Impairment Research (4 papers) and Amyloidosis: Diagnosis, Treatment, Outcomes (4 papers). Ruth Motter collaborates with scholars based in United States, Canada and Ireland. Ruth Motter's co-authors include Peter Seubert, Dale Schenk, Kelly Johnson‐Wood, Ivan Lieberburg, Robin Barbour, Dora Games, Douglas Galasko, Christopher M. Clark, Dora Kholodenko and Lisa McConlogue and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Neuroscience.

In The Last Decade

Ruth Motter

25 papers receiving 2.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Reduction of β‐amyloid peptide₄₂ in the cerebrospinal fluid of patients with Alzheimer's disease

1995 568 citations Ruth Motter, Dora Kholodenko et al. profile →
Amyloid precursor protein processing and Aβ ₄₂ deposition in a transgenic mouse model of Alzheimer disease

1997 553 citations Kelly Johnson‐Wood, Ruth Motter et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ruth Motter United States	18	2.2k	881	803	493	463	25	2.6k
Yukitsuka Kudo Japan	32	2.0k 0.9×	715 0.8×	874 1.1×	387 0.8×	408 0.9×	110	3.1k
Caroline E. Hope United States	7	2.0k 0.9×	689 0.8×	504 0.6×	460 0.9×	675 1.5×	8	2.5k
Catharine Joachim United States	18	2.8k 1.3×	1.6k 1.9×	632 0.8×	427 0.9×	694 1.5×	28	3.7k
Jacob M. Basak United States	12	1.5k 0.7×	771 0.9×	314 0.4×	299 0.6×	569 1.2×	14	2.3k
Lih-Fen Lue United States	15	1.8k 0.8×	786 0.9×	244 0.3×	432 0.9×	669 1.4×	16	2.4k
Scot Styren United States	19	1.6k 0.7×	838 1.0×	356 0.4×	458 0.9×	885 1.9×	31	2.9k
Sue G. Griffith United States	7	1.4k 0.7×	378 0.4×	371 0.5×	471 1.0×	546 1.2×	12	2.0k
Elizabeth A. Eckman United States	24	2.6k 1.2×	1.6k 1.8×	244 0.3×	644 1.3×	611 1.3×	40	3.9k
Daniel Paris United States	37	2.0k 0.9×	1.3k 1.5×	347 0.4×	510 1.0×	1.3k 2.7×	100	3.9k

Countries citing papers authored by Ruth Motter

Since Specialization

Citations

This map shows the geographic impact of Ruth Motter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruth Motter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruth Motter more than expected).

Fields of papers citing papers by Ruth Motter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruth Motter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruth Motter. The network helps show where Ruth Motter may publish in the future.

Co-authorship network of co-authors of Ruth Motter

This figure shows the co-authorship network connecting the top 25 collaborators of Ruth Motter. A scholar is included among the top collaborators of Ruth Motter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruth Motter. Ruth Motter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Barash, Jason R., et al.. (2022). Dual-Toxin (“Bivalent”) Infant Botulism in California, 1976-2020: Epidemiologic, Clinical, and Laboratory Aspects. The Journal of Pediatrics. 253. 8–13. 3 indexed citations

Motter, Ruth, et al.. (2018). Safety and immunogenicity of investigational recombinant botulinum vaccine, rBV A/B, in volunteers with pre-existing botulinum toxoid immunity. Vaccine. 36(15). 2041–2048. 26 indexed citations

Bergeron, M., et al.. (2013). In vivo modulation of polo-like kinases supports a key role for PLK2 in Ser129 α-synuclein phosphorylation in mouse brain. Neuroscience. 256. 72–82. 42 indexed citations

Garofalo, Albert W., Marc Adler, Danielle L. Aubele, et al.. (2013). Discovery of 4-alkylamino-7-aryl-3-cyanoquinoline LRRK2 kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 23(7). 1974–1977. 23 indexed citations

Motter, Ruth, Armanda Rodrigues, Linnea Diep, et al.. (2013). Development of an enzyme-linked immunosorbent assay (ELISA) to measure the level of tyrosine hydroxylase protein in brain tissue from Parkinson's disease models. Journal of Neuroscience Methods. 215(2). 245–257. 13 indexed citations

Schroeter, Sally, Elizabeth Brigham, Ruth Motter, et al.. (2010). P3‐321: APP‐selective gamma secretase inhibitor ELND006 effects on brain parenchymal and vascular amyloid beta in the PDAPP mouse model of Alzheimer's disease. Alzheimer s & Dementia. 6(4S_Part_18). 3 indexed citations

Black, Ronald S., Reisa A. Sperling, Beth Safirstein, et al.. (2010). A Single Ascending Dose Study of Bapineuzumab in Patients With Alzheimer Disease. Alzheimer Disease & Associated Disorders. 24(2). 198–203. 136 indexed citations

Seubert, Peter, Robin Barbour, Karen Khan, et al.. (2008). Antibody Capture of Soluble Aβ Does Not Reduce Cortical Aβ Amyloidosis in the PDAPP Mouse. Neurodegenerative Diseases. 5(2). 65–71. 55 indexed citations

McConlogue, Lisa, Manuel Buttini, John P. Anderson, et al.. (2007). Partial Reduction of BACE1 Has Dramatic Effects on Alzheimer Plaque and Synaptic Pathology in APP Transgenic Mice. Journal of Biological Chemistry. 282(36). 26326–26334. 231 indexed citations

10.

Chen, Guiquan, Karen Chen, Dione Kobayashi, et al.. (2007). Active β-Amyloid Immunization Restores Spatial Learning in PDAPP Mice Displaying Very Low Levels of β-Amyloid. Journal of Neuroscience. 27(10). 2654–2662. 41 indexed citations

11.

Slemmon, J. Randall, et al.. (2006). Distribution of Aβ peptide in whole blood. Journal of Chromatography B. 846(1-2). 24–31. 11 indexed citations

12.

Buttini, Manuel, Eliezer Masliah, Robin Barbour, et al.. (2005). β-Amyloid Immunotherapy Prevents Synaptic Degeneration in a Mouse Model of Alzheimer's Disease. Journal of Neuroscience. 25(40). 9096–9101. 135 indexed citations

13.

Brayden, David J., Siobhán McClean, Robin Barbour, et al.. (2001). Encapsulation in biodegradable microparticles enhances serum antibody response to parenterally-delivered β-amyloid in mice. Vaccine. 19(30). 4185–4193. 18 indexed citations

14.

Sunderland, Trey, Benjamin Wolozin, Douglas Galasko, et al.. (1999). Longitudinal stability of CSF tau levels in Alzheimer patients. Biological Psychiatry. 46(6). 750–755. 82 indexed citations

15.

Galasko, Douglas, L. Chang, Ruth Motter, et al.. (1998). High Cerebrospinal Fluid Tau and Low Amyloid β42 Levels in the Clinical Diagnosis of Alzheimer Disease and Relation to Apolipoprotein E Genotype. Archives of Neurology. 55(7). 937–937. 369 indexed citations

16.

Ellis, Ronald J., Peter Seubert, Ruth Motter, et al.. (1998). Cerebrospinal fluid tau protein is not elevated in HIV-associated neurologic disease in humans. Neuroscience Letters. 254(1). 1–4. 32 indexed citations

17.

Galasko, Doug, Christopher M. Clark, Lei Chang, et al.. (1997). Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology. 48(3). 632–635. 110 indexed citations

18.

Johnson, G V, et al.. (1997). The τ Protein in Human Cerebrospinal Fluid in Alzheimer's Disease Consists of Proteolytically Derived Fragments. Journal of Neurochemistry. 68(1). 430–433. 133 indexed citations

19.

Schenk, Dale, Ivan Lieberburg, Ruth Motter, & Peter Seubert. (1996). The Effect of Apolipoprotein E Genotype on Biochemical Markers of Alzheimer's Disease. Annals of the New York Academy of Sciences. 802(1). 92–100. 1 indexed citations

20.

Schwartz, Benjamin, et al.. (1989). Investigation of an Outbreak of Moraxella Conjunctivitis at a Navajo Boarding School. American Journal of Ophthalmology. 107(4). 341–347. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact